219 related articles for article (PubMed ID: 14973554)
1. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(7):1448-56. PubMed ID: 14973554
[TBL] [Abstract][Full Text] [Related]
2. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Surgery; 2004 May; 135(5):555-62. PubMed ID: 15118593
[TBL] [Abstract][Full Text] [Related]
3. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
4. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2003 Nov; 311(3):786-92. PubMed ID: 14623342
[TBL] [Abstract][Full Text] [Related]
5. EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.
Cho MC; Cho SY; Yoon CY; Lee SB; Kwak C; Kim HH; Jeong H
PLoS One; 2015; 10(7):e0130975. PubMed ID: 26177500
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
[TBL] [Abstract][Full Text] [Related]
7. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
J Am Coll Surg; 2004 Jun; 198(6):953-9. PubMed ID: 15194078
[TBL] [Abstract][Full Text] [Related]
8. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Jan; 23(2):465-73. PubMed ID: 14724575
[TBL] [Abstract][Full Text] [Related]
9. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Benoit E; Ashley SW; Whang EE
Br J Cancer; 2004 Oct; 91(7):1384-90. PubMed ID: 15316565
[TBL] [Abstract][Full Text] [Related]
10. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo.
Yuan W; Chen Z; Chen Z; Wu S; Guo J; Ge J; Yang P; Huang J
Neoplasma; 2012; 59(1):105-13. PubMed ID: 22103904
[TBL] [Abstract][Full Text] [Related]
11. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
[TBL] [Abstract][Full Text] [Related]
12. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Cancer Res; 2004 Jun; 64(11):3987-93. PubMed ID: 15173012
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B
Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820
[TBL] [Abstract][Full Text] [Related]
14. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
15. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
16. [Influence of EphA2 siRNA transfection on the biological behavior of human ovarian carcinoma cell].
Han LP; Li MM; Zhang XX; Geng LN; Suo ZH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):877-81. PubMed ID: 24490493
[TBL] [Abstract][Full Text] [Related]
17. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
18. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Fukuchi M; Nakajima M; Kuwano H
Int J Cancer; 2003 Feb; 103(5):657-63. PubMed ID: 12494475
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of EphA2 and FAK in ovarian carcinoma.
Shahzad MM; Lu C; Lee JW; Stone RL; Mitra R; Mangala LS; Lu Y; Baggerly KA; Danes CG; Nick AM; Halder J; Kim HS; Vivas-Mejia P; Landen CN; Lopez-Berestein G; Coleman RL; Sood AK
Cancer Biol Ther; 2009 Jun; 8(11):1027-34. PubMed ID: 19395869
[TBL] [Abstract][Full Text] [Related]
20. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
